title: Genomic profiling shows increased glucose metabolism in luminal B breast cancer.
abstract: We had previously reported a close association between pathological response and the maximum tumor standardized uptake value (SUVmax) measured by (18)F-fluorodeoxyglucose positron emission tomography prior to chemotherapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that glucose hypermetabolism by luminal B tumors may result in chemotherapy responsiveness. Using a single-gene expression assay, TargetPrint® (Agendia) and a 70-gene expression classifier, MammaPrint® (Agendia), we divided 20 patients with ER-positive primary breast cancer into luminal A and luminal B subtypes and compared the tumor SUVmax value between the two groups. A significantly higher SUVmax was measured for luminal B tumors (n=10; mean±SD, 7.6±5.6) than for luminal A tumors (n=10; mean±SD, 2.6±1.2; p=0.01). Glucose hypermetabolism could help predict intrinsic subtyping and chemotherapy responsiveness as a supplement to ER, progesterone receptor, HER2, and Ki-67 histochemical scores.
authors.affiliation: Department of Breast Oncology, International Medical Center, Saitama Medical School, Saitama, Japan.
authors.forename: Shigeto
authors.initials: S
authors.lastname: Ueda
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Saeki
authors.forename: Hideki
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigekawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Matsuura
authors.forename: Noriko
authors.initials: N
authors.lastname: Nakamiya
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sano
authors.forename: Hiroko
authors.initials: H
authors.lastname: Shimada
authors.forename: Eiko
authors.initials: E
authors.lastname: Hirokawa
authors.forename: Akihiko
authors.initials: A
authors.lastname: Osaki
keywords: Breast neoplasms; Estrogen receptor; Fluorodeoxyglucose positron emission tomography; Glucose metabolism